Silas Inman, Senior Vice President, Content, joined MJH Life Sciences™ in early 2011 as one of the company's first web editors. In this position, he built OncLive.com from a fledgling web platform to a leading source of oncology news for community oncologists via in-depth reporting of breaking news from major medical conferences and the launch of OncLive® TV.
Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands and for quickly transforming acquisitions into high-functioning business units. Prior to joining MJH, Silas, who attended Eastern Michigan University, was an EMT, frontend web developer, and social media/SEO expert. Follow him on Twitter @SilasInman or email him at sinman@mjhlifesciences.com
FDA Grants Priority Review to Ivosidenib for IDH1-Mutant AML
February 15th 2018Agios Pharmaceuticals announced that the FDA has granted a priority review designation to its targeted therapy, ivosidenib (AG-120), for the treatment of patients with relapsed/refractory IDH1-mutant acute myeloid leukemia (AML).
FDA Grants Priority Review to Daratumumab for First-line Treatment of Multiple Myeloma
January 23rd 2018Daratumumab (Darzalex) in combination with bortezomib (Velcade), melphalan, and prednisone (VMP), has been granted a priority review designation by the FDA for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
Investigating the Use of Olaparib and Durvalumab in BRCA-mutant Breast Cancer Treatment
December 28th 2017The combination of olaparib (Lynparza) and durvalumab (Imfinzi) for pretreated patients with germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer shows great promise for future treatment.
Stereotactic Radiotherapy Device Approved by FDA to Treat Early Stage Breast Cancer
December 27th 2017The FDA has approved a novel breast-specific stereotactic body radiotherapy (SBRT) device known as GammaPod as a treatment for patients with early breast cancer, based on findings from a 17-patient study.
FDA Approves Pertuzumab Regimen as Adjuvant Treatment for HER2+ Breast Cancer
December 21st 2017The FDA has approved the combination of pertuzumab (Perjeta), trastuzumab (Herceptin) and chemotherapy as an adjuvant treatment for patients with HER2-positive early breast cancer at high risk for recurrence.
Letermovir Granted FDA Approval for CMV Prophylaxis After Transplant
November 9th 2017The FDA has approved letermovir (Prevymis) to prevent cytomegalovirus (CMV) infection in adult CMV-seropositive patients treated with an allogeneic hematopoietic stem cell transplant (HSCT), based on a significant reduction in CMV infection rates in a phase III study.
Acalabrutinib Granted FDA Approval for Mantle Cell Lymphoma Treatment
October 31st 2017The FDA has granted an accelerated approval to acalabrutinib (Calquence) as a treatment for adult patients with mantle cell lymphoma (MCL) following at least 1 prior therapy, based on objective response rates (ORR) in a single-arm trial.
Durvalumab Shows "Clear Improvement" in Lung Cancer Outcomes
September 14th 2017"This is a clear improvement in the outcome, with increased PFS—by about 11 months—consistent improvement in response rate, and decreases in the development of metastatic disease," said lead investigator Luis Paz-Ares, MD, chair, Medical Oncology Department, Hospital Universitario Doce de Octubre.
Loperamide Plus Budesonide Lessons Diarrhea With Neratinib in HER2+ Breast Cancer
December 9th 2016According to findings from a phase II trial, prophylactic treatment with a combination of loperamide and budesonide reduced the rate of all-grade diarrhea associated with neratinib to 65%, compared with 95.4% observed in the ExteNET trial.